Abstract 174P
Background
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival of <12%. Patients typically present with advanced disease. Developing a blood-based screening panel could offer a simple test without requiring invasive procedures, enabling earlier detection and accelerate drug discovery. This study integrated plasma-based proteomic, tissue and clinical data supported by the PURPLE pancreatic cancer registry to identify novel biomarkers that can aid screening for early-stage disease, predict survival outcomes and guide drug discovery.
Methods
Unbiased quantitative comparative proteomics analysis was performed via a 16-window diaPASEF method on a TIMS TOF Pro mass spectrometer. Data was searched with DIA-NN (v1.8.3) in library-free mode and normalisation using RUVIIIC (v1.0.19). Matched clinicopathological and survival data was extracted from the PURPLE pancreatic cancer registry.
Results
Proteomic analysis of plasma from 203 participants showed distinct protein changes between PDAC patients with early and late-disease stage. Plasma from 120 PDAC, 69 healthy controls and 14 alternative pancreatic pathologies were analysed. A total of 919 proteins were detected (mean of 400 in each sample). When comparing PDAC with healthy controls, 246 significant differentially expressed proteins were identified (false discovery rate, FDR <0.1). Hierarchical data clustering analysis demonstrated a clear protein signature of the top 40 differentially expressed proteins in PDAC. When comparing early versus late-stage PDAC, 12 significantly differentially expressed proteins were identified. Reactome pathway analysis revealed significant up-regulation in immune response and wound healing pathways, and down-regulation of lipid and glucose metabolism in PDAC. These findings suggest that abnormal processes are quantifiable and can be detected earlier in the blood.
Conclusions
A unique PDAC protein signature was identified when comparing PDAC to healthy controls and alternative pancreatic pathologies. The dysregulated proteins identified have potential therapeutic implications that could accelerate selection of drug targets, inform clinical trial design, and enable earlier blood-based PDAC screening.
Clinical trial identification
Australian New Zealand Clinical Trial Registy Trial Acronym: PURPLE Registry Pancreatic cancer: Understanding Routine Practice and Lifting End Results (PURPLE). A Prospective Pancreatic Cancer Clinical Registry Registration number: ACTRN12617001474347 Registered: 08/03/2017.
Editorial acknowledgement
Legal entity responsible for the study
Walter & Eliza Hall Institute.
Funding
Hemstritch Centenary Fellowship ( Awarded to Dr Belinda Lee), Philanthropic funding from the Hemstritch Foundation & Segal Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract